Hepatitis C Virus (HCV) infection is a major global health concern, with significant morbidity and mortality associated with chronic liver disease. While the advent of Direct-Acting Antiviral agents (DAAs) has revolutionized HCV treatment, challenges such as viral resistance and access to therapy persist. In this article, we review recent advancements in hepatitis C treatment, focusing on novel antiviral therapies that offer promise for further improving patient outcomes. We explore host-targeted therapies, combination regimens, therapeutic vaccines, and immune modulators as innovative approaches to enhance viral clearance and reduce liver-related complications. Additionally, we discuss challenges such as access to treatment, management of comorbidities, and global elimination efforts. By embracing these novel antiviral strategies and addressing existing barriers, we can advance towards the goal of hepatitis C elimination and improve the lives of individuals affected by this chronic viral infection.
HTML PDFShare this article
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
